Chelation therapy to remove potentially toxic levels of lead was not associated with a reduction in CV events in post-MI patients with diabetes in the TACT2 trial.
Chelation therapy to remove potentially toxic levels of lead from the blood was not associated with a reduction in cardiovascular events in post-, which had shown a reduction in cardiovascular events with edetate disodium chelation therapy in post-MI patients, with a particularly marked effect in those with diabetes.
Chief investigator of the TACT2 trial, Gervasio Lamas, MD, chair of medicine at Mount Sinai Medical Center in Miami, Florida, suggested that the different results from the TACT and TACT2 trials might have been due to lower blood levels of lead in the patients enrolled in the new trial, a reflection of the improved public health interventions that have successfully reduced lead exposure in most developed countries over the past several decades. He pointed out that from 2003-2010, when the first TACT trial was ongoing, blood lead levels in the US averaged 17 mcg/L. Due to public health interventions, blood lead levels from 2015-2020 averaged 10 mcg/L — a 41% drop. And in the TACT2 population, blood lead levels were even lower at baseline at 9 mcg/L. "So, my hypothesis is that US/Canadian blood levels have markedly dropped since 2003, reducing the potential therapeutic impact of further lowering blood lead levels," Lamas said. He concluded that: "TACT2 does not support the use of EDTA chelation for risk reduction in stable post-MI patients with diabetes in the US or Canada." But he added: "If we had to do this over again, I think we could target patients with higher lead levels. If we look at lead levels worldwide, we see that in the developed world, lead levels are in the range of around 10 mcg/L, but in the developing world, lead levels are often above 60 mcg/L." Lamas presented the TACT2 study today at the American College of Cardiology's Annual Scientific Session in Atlanta. Discussing the study at the late-breaking clinical trials session, Richard Chazal, MD, medical director of the Heart and Vascular Institute, Lee Memorial Health System, Fort Myers, Florida, thanked Lamas for conducting this trial to clarify the issue of whether chelation therapy could be beneficial in post-MI patients. "This can be a perplexing problem when patients ask us about this therapy, especially as FDA guidelines express some ambiguity, pointing out that this therapy is not FDA approved for this indication, but the TACT trial had suggested a signal," Chazal noted. Also commenting on the study at an ACC press conference, Suzanne Baron, MD, Massachusetts General Hospital, Boston , suggested other factors that may have contributed to the neutral result, including a "less than perfect" compliance rate, with 68% of patients completing the full course of chelation infusions; and the fact that pharmacological therapy had advanced considerably in the years between the two trials, which may have overcome the benefit that chelation could offer.The previous TACT trial, conducted from 2003-2012, randomized 1702 patients with a prior MI to placebo or EDTA infusions, and found that cardiovascular events were reduced in the EDTA group , with aLamas noted that, in addition to the lower lead levels in the TACT2 population, patients in the second study also had more advanced diabetes and more severe associated health impacts than those in the first TACT trial, reducing the trial's ability to meaningfully affect clinical outcomes. He suggested, however, that the study's findings in terms of overall lead reduction could still be relevant for informing health interventions in the majority of the world where lead exposure is more common. "Our method of treatment was effective at reducing lead, even in patients starting with low lead levels, and it was safe," Lamas said. "In most countries outside of North America and western Europe, lead remains a serious cardiovascular and neurological problem," he said. "This study may be more relevant to those areas of the world, but this is a hypothesis that requires further study."All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC. This website also contains material copyrighted by 3rd parties.
Cardiovascular Risk CV Risk Factors Cardiovascular Risk Factors Cardiovascular Risk Management Toxicology Toxicity Poisoning Toxins Heavy Metal Toxicity Environmental Medicine Environmental Health Blood Chelation Therapy Angina Angina Pectoris Myocardial Infarction Florida Stroke Cerebrovascular Accident CVA - Cerebrovascular Accident Healthcare And Medical Technology
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
The duration of anorexia doesn't influence the benefit of enhanced cognitive-behavioral therapy (CBT-E).Adolescents with anorexia nervosa, irrespective of the duration of their illness, can derive similar benefits from intensive enhanced cognitive-behavioral therapy.
Read more »
Paralyzed man who can walk again shows potential benefit of stem cell therapyA Mayo Clinic study used a patient's stem cells to help repair the spinal cord.
Read more »
Paralyzed man who can walk again shows potential benefit of stem cell therapyA man who was paralyzed from the neck down after a surfing accident seven years ago is now able to stand and walk on his own, thanks in part to a potentially groundbreaking stem cell treatment.
Read more »
Paralyzed man who can walk again shows potential benefit of stem cell therapyA man who was paralyzed from the neck down after a surfing accident seven years ago is now able to stand and walk on his own, thanks in part to a potentially groundbreaking stem cell treatment.
Read more »
Paralyzed man who can walk again shows potential benefit of stem cell therapyA man who was paralyzed from the neck down after a surfing accident seven years ago is now able to stand and walk on his own, thanks in part to a potentially groundbreaking stem cell treatment.
Read more »
Personal Perspective: Psychodrama therapy gave me 10 years of therapy in 1 day.A Personal Perspective: Psychodrama is a form of group therapy. Individuals process their childhood traumas by acting out early memories together and rewriting their family stories.
Read more »